Skip to main content
. 2019 Jul 16;10:1653. doi: 10.3389/fimmu.2019.01653

Figure 3.

Figure 3

Monitoring of disease course, immunoglobulin and B-cell subset levels in INS patients who developed a severe de-novo hypogammaglobulinemia following anti-CD20 treatment. RTX, rituximab; OFA, ofatumumab; SCIg, subcutaneous immunoglobulin infusion; IVIg, intravenous immunoglobulin infusion; PDN, prednisone; MMF, mycophenolate mofetil; CNIs, calcinuerin inhibitors, IFN, interferon.